The expansion of the cell and gene therapy market is anticipated to be constrained by limited reimbursements that prohibit patients from accessing treatments. The increasing price, patient volume, and number of CGTs on the Cell and Gene Therapy Market are likely to change the reimbursement model for CGTs and have a 5–10% impact on payer budgets, according to research by Trinity Life Sciences, a life sciences solution provider, on large national and regional commercial health insurance plans in the US. Due of the uncertainties surrounding the payment of ancillary charges, payers are aware that finance must be created for cost management. High-cost CGT is not being provided to patients due to limited reimbursements and ambiguous insurance coverage, which is predicted to restrain market growth.
Read More @ https://cmiinfonest.blogspot.com/2022/12/cell-and-gene-therapy-market-global.html
